Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNIA-1: ANV419 in advanced cutaneous melanoma
NCT05578872Phase 2Completed
- Sponsor
- Anaveon
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of ANV419 in cutaneous melanoma (CM) (2 arms), sponsored by Anaveon. Primary endpoint: Objective Response Rate at 12 months. Started Dec 2022; status: completed.
02
Drugs
ANV419
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05578872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578872.